Neurocrine completes $2.9B acquisition of Soleno, adding first FDA-approved treatment for Prader-Willi syndrome hunger.

Neurocrine Biosciences has finalized its $2.9 billion acquisition of Soleno Therapeutics, gaining VYKAT™ XR, the first FDA-approved drug for treating hyperphagia in Prader-Willi syndrome patients aged 4 and older. This acquisition strengthens Neurocrine's rare disease portfolio and expands its commercial offerings alongside existing therapies like INGREZZA® and CRENESSITY®. Prader-Willi syndrome is a rare genetic disorder causing severe hunger and behavioral issues, significantly impacting patients' quality of life. Neurocrine aims to increase access to VYKAT XR and leverage its expertise to support the Prader-Willi community while advancing treatments for rare diseases.